Refine by
Biotherapeutics Articles & Analysis
140 news found
” Creative BioMart remains committed to offering scientifically robust services that support advancements in immunology, oncology, infectious disease research, and biotherapeutic development. For more information, please visit https://www.creativebiomart.net/epitope-mapping.htm. ...
Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...
It will also use this influx of funds to push forward research of new microbial therapeutics and development of FDA-approved live biotherapeutic products (LBP). Herb Lin, a managing partner at TPTF, first learned of Bened through his fund’s investment in Finch Therapeutics, a microbiome therapy company now listed on the NASDAQ. ...
Bened Biomedical Co, LTD., the global leader in psychobiotics with clinical studies, has acquired its US distributor Oryx Biomedical, Inc., who is pioneering the translation of microbiome research into impactful biotherapeutics and is one of the earliest stage companies bringing the gut-brain axis category of probiotics to the market. ...
Protein Metrics Inc., a leading provider of biopharmaceutical and proteomics analysis software, announced today a new partnership to advance glycoproteomics and biotherapeutics tools and research Macquarie University’s Analytical Glycoimmunology Group and Protein Metrics Inc. today have launched a strategic partnership scheme to further advance glycoproteomics and ...
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has entered into an exclusive world-wide patent license with Massachusetts Institute of Technology (MIT), Brigham and Woman’s Hospital, and Massachusetts General Hospital. The associated patents broadly cover foundational elements for the rapid, targeted delivery of drugs, including ...
NTCD-M3 NTCD-M3 is a single strain biotherapeutic being developed by Destiny Pharma for the prevention of the recurrence of infections caused by toxic strains of the gut bacteria Clostridioides difficile (C. diff). ...
Specializing in drug formulation, the highly specialized CRO service provider CD Formulation has accumulated abundant experience in the custom synthesis of increased bioavailability excipients. To meet the requirements of different drug research projects, excipients can be tailor-made in varied specifications and volumes. Recently, adding increased bioavailability excipients in drug formulations ...
(Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer ...
Glycoproteins, such as glycosyltransferases, glycosidases, erythropoietin, and cytokines, make up the majority of biotherapeutic products. Although the drugs themselves are complicated, it is urgent to develop techniques to characterize glycosylation in order to better evaluate their effects. ...
(“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the dosing of the first patient in the expansion cohorts of its ongoing Phase 1 study for IO-108. ...
(“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the appointment of Christopher Whitmore as chief financial officer. ...
The recapitalization also independently values Duet BioTherapeutics, Scopus’ pure play immuno-oncology subsidiary, at $25 ...
(“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced it has entered into a clinical trial collaboration and supply agreement with to evaluate Immune-Onc’s first-in-class myeloid checkpoint inhibitors, IO-108 and IO-202, in combination with BeiGene’s anti-PD-1 ...
(“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the first patient has been treated with IO-108, a first-in-class myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4), in a Phase 1 clinical trial in China for ...
The selected companies from seven European countries are A4Cell, AbolerIS Pharma, Abscint, ANeuroTech, Aptus, Bloomlife, Clouds of Care, E-scopics, FluoSphera, Iomed, Lattice Medical, mimiX biotherapeutics, Neomatrix, Neuropath, Predilife, Pulsify Medical, Radiomics, Regen Lab, Smart immune, Transactiva, Vidac Pharma Ltd., Leucid Bio, miDiagnostics, MRM Health & Yoni ...
Buechel will provide valuable input to product development and go to market strategy leveraging her breadth of experience in the medical diagnostics and biotherapeutics space.” “I am excited for this opportunity to join the MOBILion Board of Directors” said Ms. ...
About Waisman Biomanufacturing With its state-of-art production facility in Madison, WI, and its expert personnel, Waisman Biomanufacturing has become a leading GMP contract manufacturing organization (CMO) which manufactures a wide range of biotherapeutics for clinical trials. The products include gene therapies, cell therapeutics, and both therapeutic and prophylactic vaccines. ...
(NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its board of directors (the “Board”) has adopted a limited-duration shareholder rights plan (the “Rights Plan”). ...
” Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics. ...